Moderna CFO sells 34,836 shares at $134.49

Moderna’s CFO exercised options and sold a total of 34,836 shares in pre‑planned trades under a Rule 10b5-1 plan.

Rhea-AI Filing Summary

Moderna, Inc. (MRNA) reported that Chief Financial Officer James M. Mock exercised options for 19,836 shares of common stock at an exercise price of $30.96 per share on September 10, 2026, and received the underlying shares.

On the same date, he sold 34,836 shares of common stock at $134.49 per share in market transactions, including the 19,836 shares from the option exercise and an additional 15,000 shares, pursuant to a Rule 10b5-1 trading plan adopted on June 9, 2026. Following the exercise, he held 43,642 stock options expiring March 1, 2035.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 4 txns

Insider Mock James M

Role Chief Financial Officer

Sold 34,836 shs ($4.69M)

Approx. gross sale proceeds $4.69M

Approx. exercise cost $614K

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy) F1, F2	19,836	$0.00	$0.00
Exercise	Common Stock F1	19,836	$30.96	$614K
Sale	Common Stock F1	19,836	$134.49	$2.67M
Sale	Common Stock F1	15,000	$134.49	$2.02M

Holdings After Transaction: Stock Option (Right to Buy) — 43,642 contracts (Direct); Common Stock — 59,375 shares (Direct)

Footnotes (2)

1. F1. The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 9, 2026.
2. F2. 25% of this option vested and become exercisable on March 1, 2026 with the remainder vesting in twelve (12) equal quarterly installments thereafter.

Key Figures

Shares sold: 34,836 shares Option shares exercised: 19,836 shares Sale price: $134.49 per share +4 more

7 metrics

Shares sold 34,836 shares Total Moderna common shares sold by the CFO on September 10, 2026

Option shares exercised 19,836 shares Common shares acquired upon option exercise on September 10, 2026

Sale price $134.49 per share Price for the 34,836 common shares sold on September 10, 2026

Option exercise price $30.96 per share Exercise price for 19,836 stock options converted into common stock

Remaining stock options 43,642 options Stock options held by the CFO following the reported exercise

Option expiration date March 1, 2035 Expiration date of the stock option award involved in the exercise

10b5-1 plan adoption date June 9, 2026 Date the Rule 10b5-1 trading plan governing these trades was adopted

Key Terms

Rule 10b5-1 trading plan, Stock Option, vested and become exercisable

3 terms

Rule 10b5-1 trading plan regulatory

"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 9, 2026."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Stock Option financial

"25% of this option vested and become exercisable on March 1, 2026 with the remainder vesting in twelve (12) equal quarterly installments thereafter."

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

vested and become exercisable financial

"25% of this option vested and become exercisable on March 1, 2026 with the remainder vesting in twelve (12) equal quarterly installments thereafter."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did MRNA’s CFO report on September 10, 2026?

James M. Mock, Moderna’s CFO, exercised options for 19,836 shares at $30.96 and on the same day sold a total of 34,836 shares at $134.49 per share in market transactions.

How many Moderna (MRNA) shares did the CFO sell and at what price?

On September 10, 2026, the CFO sold 34,836 shares of Moderna common stock in market transactions at a price of $134.49 per share.

What stock options did the Moderna (MRNA) CFO exercise in this Form 4?

He exercised 19,836 stock options for Moderna common stock at an exercise price of $30.96 per share. These options are part of a grant that expires March 1, 2035 and vests over time.

Were the Moderna (MRNA) CFO’s trades made under a Rule 10b5-1 plan?

Yes. A footnote states that the reported transactions were effected pursuant to a Rule 10b5-1 trading plan adopted on June 9, 2026, indicating the trades were pre-arranged.

How many Moderna (MRNA) stock options does the CFO hold after these transactions?

After exercising 19,836 options, the CFO is reported to hold 43,642 stock options for Moderna common stock, with these options expiring on March 1, 2035.

What is the vesting schedule mentioned for the Moderna (MRNA) CFO’s options?

A footnote explains that 25% of the option vested and became exercisable on March 1, 2026, with the remainder vesting in twelve equal quarterly installments thereafter.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/14/2026 - 04:25 PM Accepted by SEC EDGAR 09/14/2026 - 04:25 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mock James M

(Last) (First) (Middle)

C/O MODERNA, INC.

325 BINNEY STREET

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Moderna, Inc. [ MRNA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/10/2026		M(1)		19,836	A	$30.96	94,211	D
Common Stock	09/10/2026		S(1)		19,836	D	$134.49	74,375	D
Common Stock	09/10/2026		S(1)		15,000	D	$134.49	59,375	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$30.96	09/10/2026		M(1)			19,836	(2)	03/01/2035	Common Stock	19,836	$0	43,642	D

Explanation of Responses:

1. The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on June 9, 2026.

2. 25% of this option vested and become exercisable on March 1, 2026 with the remainder vesting in twelve (12) equal quarterly installments thereafter.

	/s/ James Dillon, As Attorney-in-Fact	09/14/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)